Trevena’s TRV027 heart failure candidate fails to meet primary, secondary endpoints in phase 2 trial
The randomized, double-blind, standard of care-controlled trial, dubbed BLAST-AHF, assessed three doses of TRV027 plus standard heart failure therapy compared to placebo plus standard therapy in 618 patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.